CompletedNot Applicable

In Vivo Versus Augmented Reality Exposure for Small Animal Phobia

Spain60 participantsStarted 2011-01

Plain-language summary

The aim of this study is to explore the differential efficacy of in vivo exposure versus augmented reality exposure in the treatment of specific phobia (small animals). The hypothesis is: There will not be significant statistical differences in the efficacy of in vivo exposure therapy versus augmented reality exposure in the treatment of specific phobia (small animals).

Who can participate

Age range

18 Years – 65 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Be between 18-65 years of age. * To meet current DSM-IV-TR criteria for specific phobia (animal type) * Have as the major presenting complaint anxiety in, and avoidance of, a large range of situations involving spiders or cockroaches. * A minimum of 1 year duration of the phobia. * To have scores over 4 in phobic avoidance (on a scale of 0 to 8). * Express a willingness to participate in the study. Exclusion Criteria: * To be able to put a hand inside the container with a spider or cockroach during the behavioral test. * Have other psychiatric problem in immediate need of treatment. * Have psychotic or organic symptoms. * Have heart or lung disease. * Current alcohol or drug dependence or medication.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change in Behavioral Avoidance Test (BAT, Öst, Salkovskis, and Hellström's, 1991) at pre, post intervention and 3 and 12-month follow-up periods

Timeframe: At pre (baseline), post intervention and 3 and 12-month follow-up periods

Trial details

NCT IDNCT01361074

SponsorUniversitat Jaume I

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2011-05

View on ClinicalTrials.gov More Phobic Disorders trials